Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report), retaining the price target of $10.00.
Robert Burns has given his Buy rating due to a combination of factors that highlight the potential of Perspective Therapeutics. Despite reporting a wider net loss for 2024 than initially estimated, the company maintains a strong cash position of approximately $227 million, which is expected to support operations until late 2026. This financial stability provides a solid foundation for future growth and development.
Additionally, the company has several upcoming catalysts that could drive value, including the initiation of a Phase 1 clinical trial for PSV359 and the presentation of clinical data updates for Pb]VMT-α-NET in the second half of 2025. Burns employs a discounted cash flow valuation methodology, factoring in a 60% probability of approval for NET in GEP-NETs, which supports a 12-month price target of $10 per share. While there are risks such as potential negative clinical results and regulatory delays, the overall outlook remains positive, justifying the Buy rating.
In another report released on March 27, Oppenheimer also reiterated a Buy rating on the stock with a $16.00 price target.